ReviewEpidemiology and infection2023
Epidemiology of invasive meningococcal disease worldwide from 2010-2019: a literature review.
Review in Epidemiology and infection, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of demographic and socioeconomic characteristics associated with inequalities in invasive meningococcal disease prevention in high-income countries and Latin America.Human vaccines & immunotherapeutics · 2025Pooled it
- Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.Human vaccines & immunotherapeutics · 2025Trial
- A Phase 3 study to assess the safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in healthy infants in the USA and Puerto Rico.Human vaccines & immunotherapeutics · 2025Trial
- Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.Human vaccines & immunotherapeutics · 2025Trial
- Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age.Human vaccines & immunotherapeutics · 2024Trial
- Invasive meningococcal disease over five decades in the Faroe Islands: high incidence, low mortality, and implications for vaccination policy.IJID regions · 2026Article
- Pediatric invasive meningococcal disease in Türkiye during the post-pandemic period: increased reported cases and predominance of serogroup B and severity determined by a clinical form in a multicenter hospital-based cohort.European journal of pediatrics · 2026Article
- Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy.Infectious diseases and therapy · 2026Review
- Delayed diagnosis is associated with complications following invasive meningococcal disease in Australian adolescents and young adults.Infection · 2026Article
- Podcast: Immune Persistence After Primary Vaccination with MenQuadfi.Infectious diseases and therapy · 2026Review
- Real-world effectiveness and impact of the 4CMenB vaccine against serogroup B invasive meningococcal disease: a systematic review and meta-analysis.NPJ vaccines · 2026Article
- Potential Use of Neisseria meningitidis Serogroup B Vaccines to Prevent Neisseria gonorrhoeae Infection: Epidemiological Considerations.Journal of the International AIDS Society · 2026Review
- Purpura Fulminans in a 22-Month-Old Child: Early Recognition and Favorable Outcome Without Limb Loss.Cureus · 2026Article
- Public Health Impact and Cost-Effectiveness of Revising the Adolescent Meningococcal Vaccine Schedule in the United States.PharmacoEconomics · 2026Article
- Hyperinvasive and quinolone-resistant meningococci cc4821 achieved immune evasion through capsule switching.BMC microbiology · 2026Article
- Lumbar puncture use and antibiotic treatment in newly admitted febrile children following index cases of invasive infections.BMC infectious diseases · 2026Article
- Prevention of neuroinfectious-diseases: high impact of vaccination programs - but the potential is not maxed out yet.Neurological research and practice · 2026Review
- Epidemiology and Clinical Outcomes of Meningococcal Infections in Japan: A Nationwide Inpatient Database Study From 2010 to 2023.Journal of epidemiology · 2026Article
- Nationwide epidemiology of invasive meningococcal disease in Japan, 2017-2025: implications of post-COVID-19 mobility.Tropical medicine and health · 2026Article
- Risk of Invasive Meningococcal Disease in Children Aged <11 Years in the United States.Open forum infectious diseases · 2026Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemiology of invasive meningococcal disease (IMD) is unpredictable, varies by region and age group and continuously evolves. This review aimed to describe trends in the incidence of IMD and serogroup distribution by age group and global region over time. Data were extracted from 90 subnational, national and multinational grey literature surveillance reports and 22 published articles related to the burden of IMD from 2010 to 2019 in 77 countries. The global incidence of IMD was generally low, with substantial variability between regions in circulating disease-causing serogroups. The highest incidence was usually observed in infants, generally followed by young children and adolescents/young adults, as well as older adults in some countries. Globally, serogroup B was a predominant cause of IMD in most countries. Additionally, there was a notable increase in the number of IMD cases caused by serogroups W and Y from 2010 to 2019 in several regions, highlighting the unpredictable and dynamic nature of the disease. Overall, serogroups A, B, C, W and Y were responsible for the vast majority of IMD cases, despite the availability of vaccines to prevent disease due to these serogroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.